A Clinical and Economic Comparison of Cell-Based Versus Recombinant Influenza Vaccines in Adults 18–64 Years in the United States

A Clinical and Economic Comparison of Cell-Based Versus Recombinant Influenza Vaccines in Adults 18–64 Years in the United States

Background: This analysis compares the cost-effectiveness of a cell-based influenza vaccine to a recombinant influenza vaccine, and each to no vaccination. The analysis is based on United States (US) commercial and societal perspectives. Methods: A Susceptible–Exposed–Infectious–Recovered (SEIR) tra...

Full description

Saved in:

Bibliographic Details
Main Authors:	Myron J. Levin, Neda Al Rawashdh, Liliane Mofor, Pablo Anaya, Richard M. Zur, Emily B. Kahn, Daniel Yu, Joaquin F. Mould-Quevedo
Format:	Article
Language:	English
Published:	MDPI AG 2024-10-01
Series:	Vaccines
Subjects:	cell-based influenza vaccine recombinant influenza vaccine cost-effectiveness United States
Online Access:	https://www.mdpi.com/2076-393X/12/11/1217
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Seasonal influenza vaccination: Overcoming immunosenescence with enhanced vaccines
by: Wendy Boivin, et al.
Published: (2025-06-01)

The economic rationale for cell-based influenza vaccines in children and adults: A review of cost-effectiveness analyses
by: David Fisman, et al.
Published: (2024-12-01)

Randomised immunogenicity trial comparing 2019-2020 recombinant and egg-based influenza vaccines among frequently vaccinated healthcare personnel in Israel
by: Ashley L. Fowlkes, et al.
Published: (2024-12-01)

The safety of co-administration of recombinant zoster vaccine (Shingrix) and influenza vaccines in the elderly in VAERS during 2018–2024
by: Yihao Li, et al.
Published: (2025-12-01)

Absenteeism and Productivity Loss Due to Influenza or Influenza-like Illness in Adults in Europe and North America
by: David Fisman, et al.
Published: (2024-12-01)

Early and Late Influenza Vaccine Effectiveness in South Korea During the 2023–2024 Season
by: Yu Jung Choi, et al.
Published: (2025-02-01)

A preliminary exploration of influenza-like illness surveillance and influenza vaccination in Jing’an District of Shanghai， 2017‒2023
by: HUA Ruijue, et al.
Published: (2025-04-01)

Seasonal influenza vaccines: Variability of immune responses to B lineage viruses
by: Matthew S. Miller, et al.
Published: (2024-12-01)

Influenza immunization rates, knowledge, attitudes and practices of health care workers in Iran
by: Zahra Khazaeipour, et al.
Published: (2010-10-01)

Immunogenicity and safety of concomitant administration of recombinant COVID-19 vaccine and quadrivalent inactivated influenza vaccine in Chinese adults: An open-label, randomized, controlled trial
by: Tao Huang, et al.
Published: (2024-12-01)

Protective Impact of Influenza Vaccination on Healthcare Workers
by: Yimei Tian, et al.
Published: (2024-10-01)

About influenza and flu vaccination: opinion the students’ medical school V.V. Balzhieva, L.A. Khlebnik
by: V. V. Balzhieva, et al.
Published: (2025-06-01)

Influence of perceived influenza-like symptoms on intention to receive seasonal influenza vaccination
by: Renske Eilers, et al.
Published: (2025-03-01)

SAFETY ASSESSMENT OF TWO SUBUNIT INFLUENZA VACCINES IN CHILDREN WITH A BURDENED ALLERGOANAMNEZ
by: M. G. Galitskaya, et al.
Published: (2015-08-01)

Influenza, pneumococcal, and COVID-19 vaccination coverage and hesitancy in adults with psychiatric disorders
by: Vasfiye Demir Pervane, et al.
Published: (2025-04-01)

Cell-Cultured Influenza Vaccine Enhances IFN-γ+ T Cell and Memory T Cell Responses Following A/Victoria/2570/2019 IVR-215 (A/H1N1) Infection
by: Kyu-Ri Kang, et al.
Published: (2024-12-01)

Effectiveness of the influenza vaccine for preventing laboratory-confirmed influenza infections in outpatient immunocompromised adults, 2017–2018
by: Kailey Hughes Kramer, et al.
Published: (2024-12-01)

A Retrospective Test-Negative Case-Control Study to Evaluate Influenza Vaccine Effectiveness in Preventing Influenza Among Immunocompromised Adults With a Solid Organ Transplant
by: Manon L. M. Prins, et al.
Published: (2025-05-01)

Attitudes, Beliefs, and Self-Reported Rates of Influenza and COVID-19 Vaccinations in the Canadian 2023–2024 National Influenza and Respiratory Viruses Survey
by: Samir Sinha, et al.
Published: (2024-10-01)

Safety and Influenza Infections in Children Aged 6–35 Months Receiving Cell Culture-Derived Inactivated Quadrivalent Influenza Vaccine During the 2023–2024 Influenza Season in South Korea
by: Hye Eun Lee, et al.
Published: (2025-05-01)

Antibody response to sequential vaccination with cell culture, recombinant, or egg-based influenza vaccines among U.S. adults
by: Thomas G. Boyce, et al.
Published: (2024-12-01)

Evaluating Families’ Opinions of Routine Influenza Vaccination in Children Under 5 Years of Age in Spain
by: Sílvia Burgaya-Subirana, et al.
Published: (2025-01-01)

Coverage of influenza vaccination and influencing factors among healthcare workers in Shandong Province, China, 2021–2022
by: Yuwei Liu, et al.
Published: (2024-12-01)

Cost-Effectiveness of Adjuvanted Influenza Vaccine Compared with Standard and High-Dose Influenza Vaccines for Persons Aged ≥50 Years in Spain
by: Alberto Perez-Rubio, et al.
Published: (2025-03-01)

The Relevance of Tetravalent Influenza Vaccines. World experience
by: A. D. M. E. Osterhaus
Published: (2018-09-01)

EFFECTIVENESS OF CROSS-PROTECTIVE RECOMBINANT INFLUENZA VACCINE BASED ON CONSERVED EPITOPES OF VIRAL PROTEINS М2 AND HEMAGGLUTININ
by: L. A. Stepanova, et al.
Published: (2018-01-01)

Real-world effectiveness of live attenuated influenza vaccines (LAIV) and inactivated influenza vaccines (IIV) in children from 2003 to 2023: a systematic literature review and network meta-analysis
by: Anke L. Stuurman, et al.
Published: (2025-12-01)

The clinical and economic value of enhanced influenza vaccines for the elderly in Argentina
by: Analía Urueña, et al.
Published: (2024-12-01)

Disparities in Seasonal Influenza Vaccination in Europe
by: Katinka M. Giezeman‐Smits, et al.
Published: (2025-07-01)

Immunisation of young children against influenza — evidence review
by: V. A. Bulgakova, et al.
Published: (2022-10-01)

A Modified Novel Validated High-Throughput Hemagglutinin Inhibition Assay Using Recombinant Virus-like Particles and Human Red Blood Cells for the Objective Evaluation of Recombinant Hemagglutinin Nanoparticle Seasonal Influenza Vaccine
by: Timothy S. Vincent, et al.
Published: (2024-11-01)

Addressing influenza in Bangladesh: closing evidence and policy gaps with strategic interventions
by: Md Zakiul Hassan, et al.
Published: (2025-06-01)

Advantages of Broad-Spectrum Influenza mRNA Vaccines and Their Impact on Pulmonary Influenza
by: Ziqi Cheng, et al.
Published: (2024-12-01)

POTENTIAL OF THE RUSSIAN FEDERATION IN EXPORTS OF ANTI-INFLUENZA VACCINES IN LATIN AMERICAN COUNTRIES
by: V. P. Trukhin, et al.
Published: (2019-01-01)

Comparative effectiveness of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) in children over multiple influenza seasons (2019–2023)
by: Allyn Bandell, et al.
Published: (2025-08-01)

Cross-protection against homo and heterologous influenza viruses via intranasal administration of an HA chimeric multiepitope nanoparticle vaccine
by: Yongqiang Zhao, et al.
Published: (2025-02-01)

Influenza knowledge and barriers to vaccination in immunosuppressed patients in the pediatric rheumatology clinic
by: Julia G. Harris, et al.
Published: (2024-12-01)

Factors affecting influenza vaccine uptake among healthcare providers at a tertiary hospital in Mysuru, India: a questionnaire-based survey
by: Naviya Kafle, et al.
Published: (2025-08-01)

Vaccination and treatment of influenza: achievements and challenges
by: N. I. Briko, et al.
Published: (2021-06-01)

Analysis on willingness and its influencing factors of influenza vaccination among HCWs in Quzhou in 2022–2023 influenza season
by: Wangfeng Zheng, et al.
Published: (2025-12-01)